Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Total Debt (2023 - 2025)

Kura Oncology (KURA) has disclosed Total Debt for 3 consecutive years, with $9.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Debt rose 1.97% to $9.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.7 million, a 1.97% increase, with the full-year FY2025 number at $9.7 million, up 1.97% from a year prior.
  • Total Debt was $9.7 million for Q4 2025 at Kura Oncology, roughly flat from $9.7 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $9.7 million in Q4 2025 to a low of $9.2 million in Q1 2023.
  • A 3-year average of $9.5 million and a median of $9.4 million in 2024 define the central range for Total Debt.
  • Peak YoY movement for Total Debt: grew 1.91% in 2024, then increased 2.12% in 2025.
  • Kura Oncology's Total Debt stood at $9.3 million in 2023, then increased by 2.05% to $9.5 million in 2024, then rose by 1.97% to $9.7 million in 2025.
  • Per Business Quant, the three most recent readings for KURA's Total Debt are $9.7 million (Q4 2025), $9.7 million (Q3 2025), and $9.6 million (Q2 2025).